Alteration of Cyclosporin-A Pharmacokinetics after Experimental Spinal Cord Injury
Authors:
- Gabriel Guízar-SahagúnGGGabriel Guízar-Sahagún
- Dolores CorreaDCDolores Correa
- Roberto KretschmerRKRoberto Kretschmer
- Israel GrijalvaIGIsrael Grijalva
- Francisco J. Flores-MurrietaFFFrancisco J. Flores-Murrieta
- Gilberto Castañeda-HernándezGCGilberto Castañeda-Hernández
- Alberto OdorAOAlberto Odor
- Rosa M. LópezRLRosa M. López
- Rebecca Franco-BourlandRFRebecca Franco-Bourland
- Ana L. EspitiaAEAna L. Espitia
- Hermelinda Salgado-CeballosHSHermelinda Salgado-Ceballos
- 1 May 1996
- journal article
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 13 (5) , 267-272
Abstract
The pharmacokinetics of the immunosuppressive agent cyclosporin-A (CsA) were studied in rats submitted to spinal cord (SC) injury. A single CsA 10 mg/kg dose was given either intraperitoneally (i.p.) or orally to rats submitted to experimental SC injury at the T8 level. Twenty four hours after lesion (acute stage of SC injury) i.p. CsA bioavailability was increased, while t1/2 was prolonged. However, oral bioavailability was reduced. Seven weeks after lesion (chronic stage of SC injury) CsA bioavailability, by either route, was not significantly different from control values. Results indicate that parenteral CsA bioavailability is increased during the acute stage of SC lesion, probably due to an impaired elimination. Oral bioavailability, however, is decreased, since there is also an important reduction in gastrointestinal CsA absorption that overrides the effect of impaired elimination. Alterations in CsA pharmacokinetics appear to revert during the chronic stage of SC injury. Changes in CsA bioavailability, depending on the route of administration and on time, must be considered to design an adequate immunosuppressive treatment in SC injury.Keywords
This publication has 12 references indexed in Scilit:
- Development of post-traumatic cysts in the spinal cord of rats subjected to severe spinal cord contusionSurgical Neurology, 1994
- Behavioral Endpoint Measures for Preclinical Trials Using Experimental Models of Spinal Cord InjuryJournal of Neurotrauma, 1992
- Decreased Systemic Clearance of Lorazepam in Humans With Spinal Cord InjuryThe Journal of Clinical Pharmacology, 1991
- CyclosporineNew England Journal of Medicine, 1989
- Intracerebral xenografts of dopamine neurons: the role of immunosuppression and the blood-brain barrierExperimental Brain Research, 1989
- Immunocomplexes in rat and rabbit spinal cord after injuryExperimental Neurology, 1987
- Cyclosporine: A New Immunosuppressive Agent for Organ TransplantationAnnals of Internal Medicine, 1984
- Systemic humoral factors participating in the course of spinal cord injurySpinal Cord, 1983
- LAGRAN program for area and moments in pharmacokinetic analysisComputer Programs in Biomedicine, 1983
- SURGERY OF EXPERIMENTAL LESION OF SPINAL CORD EQUIVALENT TO CRUSH INJURY OF FRACTURE DISLOCATION OF SPINAL COLUMNJAMA, 1911